Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report

摘要: Activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR; ErbB1) – either exon 19 deletions or 21 point are associated with hypersensitivity to EGFR inhibitors (TKIs). more frequently found females, non-smokers, Asians, and patients adenocarcinoma. We report case a 51-year-old Caucasian woman metastatic NSCLC harboring an deletion although she was smoker had poorly differentiated large cell carcinoma. Following partial response on 4 months chemotherapy, patient progressed treated reversible TKI erlotinib for 3 y. The then developed resistance went receive irreversible ErbB Family Blocker afatinib 1 year, attaining at months. impressive survival time attained by our highlights clinical benefit targeting one members dissemina...